Crohns and Colitis Exchange
This is a place for members with Crohn's Disease or Ulcerative Colitis to get ... more
See All
Preferences
My Communities
My Discussions
My Email Digests
In July, she upped my medication from Humira twice a month to every week to try to get those few ulcers cleared up, and as I said, that didn't work. She said that we could go back to Remicade, but it probably wouldn't work because I didn't have that great of results from it the first time, and now my body has most likely built up antibodies to make it even less useful. Generally Imuran would be prescribed with it to help reduce the problem from the antibodies, but I can't take Imuran. The medication she wants to try me on is called Tysabri. I had never heard of it, but it's apparently some pretty scary stuff. It's used mostly for MS, but it's approved here for Crohn's also. Europe hasn't approved it for Crohn's because they say that the risk to a person with Crohn's is too great in comparison to the benefit they would receive.
I'm really quite afraid of this new drug, but I have some time to decide because there are tons of hoops you have to jump through to even have it prescribed to you. Most doctors can't prescribe it. My doctor has said that because of my response to all the other medications, this is probably my last shot. Tysabri is used as a last resort type thing, but she also said that in about 30% of patients, the reward is tremendous. The risk just happens to be that in about 0.1% of patient's prescribed the drug, they develop a brain infection that generally results in death within six months. She said that nobody has ever developed the infection while being on it for less than a year, and she wants to try me on it for about four months and then do another scope to see if it's cleared anything up. If my scope is clear and I'm feeling better, she said then we could decide it if was worth the risk of being on it long term.
I'm scared because if it doesn't work, I'm screwed, and if it does work, I'm still screwed. How do you decide between disabling stomach pain and becoming mentally handicapped or dying? And what happens after the four months, either way? I know my risk goes way up if I decide to use it long term, but like I said, I'm kind of damned if I do and damned if I don't. I can't just NOT treat the Crohn's, because of the risk of losing my pouch. My risk of colon or rectal cancer is gone, but if my pouch gets too damaged, I'll lose it and have a permanent ostomy. And I don't want that. I love my pouch. Plus, with how severe my disease is getting, even with treatment, I can't imagine without treatment. I may not be responding well to it, but it has to be helping a little bit.
I just need some insight and some opinions. And any information on Tysabri or other options any of you have heard of. Besides dieting. I'm past the point of diet controlling this. Thanks guys, and sorry my post is so long. I'm just freaking out.
I know someone on this site will more than likely have some information for you on this. I certainly hope so.
Again, you're in my prayers. Please remember that, ok?
I'm incredibly sorry that you are at such a cross roads. I'm empathetic towards your situation because I'm stuck between a rock and a hard place as well. I know you'll get a lot of advice on this board, but in the end, it's the decision you can live with that is the right one to make. I keep praying about the decisions that I need to make about my health, and I'll certainly pray about yours. I wish I knew more about Tysabri, or something to help you. You are in my thoughts!
it really seems like you're presented with a gamble - the tysabri seems like it offers the possibly get your quality of life back but you also run the risk of loosing everything. and 0.1% never seemed like a large # until you put it in that context
on the other hand, playing it safe isn't a win either. I can't imagine the frustration of all the crap you had to go through to get your pouch and then to loose it. Is there also long term disease progression to consider beyond loosing your pouch? I have no idea how these things work, and I'm so sorry you have to figure it out. When you read about Chron's you see the possibility for it to make you this sick, but to see you go through it is so frustrating and so unreal
I hope you can find peace about a decision somehow
take care
~Ali
ANYONE OUT THERE: PLEASE SHARE ANY INFO TO SHARE WITH HANNAH REGARDING TYSABRI.
1. The largest trial, "ENACT-1", included a total of 905 patients with active Crohn's disease who were randomly assigned to Natalizumab (300 mg) or placebo at weeks 0, 4, and 8. Response (defined by a decrease in the Crohn's Disease Activity Index of at least 70 points at week 10), was similar to placebo (56 vs 49 percent). Post-hoc analysis of the results in those with elevated CRP at baseline showed efficacy for Natalizumab compared with placebo.
2. The 339 responders to Natalizumab were enrolled in a follow-up trial, "ENACT-2". There was random reassignment to receive 300 mg of Natalizumab or placebo every four weeks through week 56. Patients receiving Natalizumab had significantly higher rates of sustained response (61 vs 28 percent) and remission (44 vs 26 percent) through week 36, as well as higher discontinuation rates of glucocorticoids.
A second trial, "ENCORE", included 509 patients (moderate-to-severe active Crohn's disease; active inflammation (CRP greaten than 2.87 mg/L)). Patients were randomly assigned to Natalizumab (300 mg) or placebo at weeks 0, 4, and 8. Primary endpoint: induction of a response, defined as a greater-or-equal-to 70 point reduction in the CDAI at week 8 and sustained through week 12. Response was observed significantly more often in patients assigned to Natalizumab (48 vs. 32 percent). Sustained remission (CDAI less than150) was observed significantly more often with Natalizumab (26 vs 16 percent). Frequency and types of adverse events were similar between treatment groups.
Serious adverse events occurred at a similar rate to the placebo arm in two controlled trials. However, in an open-label extension, one patient with Crohn's disease on monotherapy with Natalizumab died (JC virus-associated progressive multifocal leukoencephalopathy (PML)). Two other case reports described an association between Natalizumab and PML in patients with M.S. treated with Natalizumab and interferon beta-1a. Latent JC virus infection and viral shedding are common in immunosuppressed patients with Crohn's disease, but risk factors of JC-related disease are unclear.
Marketing of Natalizumab was suspended in February 2005 as a result, but was subsequently resumed for M.S. At least 76 additional cases of PML have occurred in those with M.S. since the drug was reintroduced (20 percent mortality rate; high degree of disability among survivors).
See Related Digestive Disorders Communities
Women's Health Newsletter
Find out what women really need.
Spotlight: Member Stories
Helpful Tips
Helpful Resources
Related News
Report Problems to the
Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Other Member Communities
- Dieting Club: 10 - 25 Lbs Member Community Share Your Tips and Support!
- Caregiving Member Community The Support and Understanding You Need!
- Parenting Friends Talking Member Community Get Support from Members Like You!
-
More Related Communities
The opinions expressed in WebMD User-generated content areas like communities, reviews, ratings, or blogs are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. User-generated content areas are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions. Some of these opinions may contain information about treatments or uses of drug products that have not been approved by the U.S. Food and Drug Administration. WebMD does not endorse any specific product, service, or treatment.
Do not consider WebMD User-generated content as medical advice. Never delay or disregard seeking professional medical advice from your doctor or other qualified healthcare provider because of something you have read on WebMD. You should always speak with your doctor before you start, stop, or change any prescribed part of your care plan or treatment. WebMD understands that reading individual, real-life experiences can be a helpful resource, but it is never a substitute for professional medical advice, diagnosis, or treatment from a qualified health care provider. If you think you may have a medical emergency, call your doctor or dial 911 immediately.
Health Solutions From Our Sponsors
©2005-2013 WebMD, LLC. All rights reserved.
WebMD does not provide medical advice, diagnosis or treatment. See additional information.


